Zinc and Prostate Cancer: A Critical Scientific, Medical, and Public Interest Issue (United States)
- 1 October 2005
- journal article
- review article
- Published by Springer Nature in Cancer Causes & Control
- Vol. 16 (8) , 901-915
- https://doi.org/10.1007/s10552-005-2367-y
Abstract
The role of zinc in the development and progression of prostate malignancy and its potential application in the prevention and treatment of prostate cancer (PCa) are contemporary critical issues for the medical/scientific community and the public-at-large. The overwhelming clinical and experimental evidence provides a compelling rational basis for the expectation and concept that prostate zinc accumulation is an important factor in the development and progression of prostate malignancy; and that zinc could be efficacious in the prevention and treatment of PCa. In contrast, various epidemiologic studies have produced divergent and conflicting results regarding the efficacy of dietary and supplemental zinc against PCa. Before reaching any definitive conclusions regarding this complex issue, one should have a complete understanding of the clinical and experimental evidence associated with the involvement of zinc in the normal and malignant prostate. Also, an understanding of interacting effects of confounding factors on the absorption, assimilation, and bioavailability of supplemental dietary zinc is important. The purpose of this review is to present the current state of the clinical and experimental information regarding zinc relationships in the normal prostate and in the pathogenesis PCa. The evidence in support of a potential beneficial effect of zinc supplement versus potential harmful effects on PCa is assessed. A discussion of the divergent results of the epidemiologic studies is presented along with a description of important factors and conditions that impact or mask the effects of dietary zinc on PCa development and progression. We also hope to bring more attention to the medical and research community of the critical need for concerted clinical and basic research regarding zinc and PCa, for the development of appropriate human prostate models to investigate these relationships, for further appropriately designed epidemiologic studies, and for future well-controlled clinical trials.Keywords
This publication has 65 references indexed in Scilit:
- RESPONSE: Re: Zinc Supplement Use and Risk of Prostate CancerJNCI Journal of the National Cancer Institute, 2004
- Prostatic Zinc and Prostate Specific Antigen: An Experimental Evaluation of Their Combined Diagnostic ValueJournal of Urology, 2003
- Reduced circulating androgen bioactivity in patients with prostate cancerThe Prostate, 2003
- Endocrine patterns in patients with benign and malignant prostatic diseasesThe Prostate, 2000
- Prolactin and testosterone regulation of mitochondrial zinc in prostate epithelial cellsThe Prostate, 1997
- Diet and prostate cancer: a case-control studyEuropean Journal Of Cancer, 1997
- Why do cancer cells have such a high glycolytic rate?Medical Hypotheses, 1990
- Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostateCancer, 1989
- The effect of zinc supplements on lipoproteins and copper statusAtherosclerosis, 1988
- Zinc and cadmium concentrations in whole tissue and in separated epithelium and stroma from human benign prostatic hypertrophic glandsThe Prostate, 1985